802906-73-6

Basic information

• Product Name: CTEP Derivative
• Synonyms: CTEP Derivative;BasiMglurant;RG 7090;RG7090;RG-7090;2-Chloro-4-((1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-yl)ethynyl)pyridine;RG7090(Basimglurant);2-Chloro-4-[2-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-yl]ethynyl]pyridine
• CAS NO: 802906-73-6
• Molecular Formula: C₁₈H₁₃ClFN₃
• Molecular Weight: 325.7673232
• Mol File: 802906-73-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 526.6±60.0 °C(Predicted)
• Appearance: /
• Density: 1.21±0.1 g/cm3(Predicted)
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 5.27±0.70(Predicted)
• Stability: Hygroscopic, Moisture Sensitive
• CAS DataBase Reference: CTEP Derivative(CAS DataBase Reference)
• NIST Chemistry Reference: CTEP Derivative(802906-73-6)
• EPA Substance Registry System: CTEP Derivative(802906-73-6)

Safety Data

• Hazardous Substances Data: 802906-73-6(Hazardous Substances Data)

Usage

Description

CTEP Derivative is a compound that has been derived from the parent compound CTEP. It possesses unique properties and characteristics that make it suitable for various applications across different industries.

Uses

Used in Pharmaceutical Industry:
CTEP Derivative is used as a therapeutic agent for the treatment of mood disorders. It functions as a potent, selective, and orally available mGlu5 negative allosteric modulator, which helps in modulating the activity of the mGlu5 receptor. This modulation can lead to the improvement of mood and emotional regulation in patients suffering from mood disorders.

Upstream product

• 74-88-4 methyl iodide 
• 824432-02-2 (Z)-2-acetylamino-3-dimethylamino-but-2-enoic acid ethyl ester 
• 90965-06-3 dimethyl 1-(1-diazo-2-oxopropyl)phosphonate 

Downstream Products

• 1034442-21-1 2-chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine mono-sulfate 

Relevant articles and documents

METHODS OF TREATMENT OF TUBEROUS SCLEROSIS COMPLEX

Provided herein are methods of treating tuberous sclerosis complex in a subject in need thereof by administering to the subject compositions comprising an mGlu5 negative allosteric modulator (NAM), having the structure of Formula (I).

METHODS FOR THE TREATMENT OF GERD WITH MGLUR5 ANTAGONISTS

The present invention relates to methods for the treatment, prevention and/or delay of progression of gastro-esophageal reflux disease (GERD) by administering compounds that act as antagonists of metabotropic glutamate type-5 receptors (mGluR5 receptor antagonists), for example compounds of formula (I) wherein A, E, R1, R2, R2 and R4 are as defined in the specification.

Imidazole derivatives

The present invention relates to imidazole derivatives of formula I wherein R1, R2, R3 and R4 are described hereinabove. These compounds can be used in the treatment or prevention of mGluR5 receptor mediated disorders. These compounds are useful, inter alia, in the treatment of genitourinary diseases.